Lunit vs Paige
A side-by-side look at scores, pricing and features — with RECATOOLS' ASEAN-aware verdict for each.
Lunit
KOSDAQ-listed Korean AI for breast and lung cancer screening
Visit
|
Paige
The first FDA-authorized AI in pathology — built on 7M+ annotated slid...
Visit
|
|
|---|---|---|
| RECATOOLS Score | 6.7 / 10 | 8.2 / 10 |
| Capability | ||
| Value for money | ||
| Ease of use | ||
| ASEAN readiness | ||
| API quality | ||
| Pricing | Enterprise | Enterprise |
| Free tier | — | Virchow & PRISM foundation models free on Hugging Face (research use; Apache 2.0 / CC-BY-NC-ND) |
| Paid from | — | Enterprise licensing — custom quote from Tempus/Paige; also on Azure Marketplace |
| Has API | ✗ | ✓ |
| Open source | ✗ | ✗ |
| Free to use | ✗ | ✗ |
| Users | — | In clinical use at hospitals and labs worldwide; training data spans 800+ labs across 45 countries |
| Founded | 2013 | 2017 |
| Maker | — | Tempus AI |
| Verdict | Lunit is the most clinically validated medical-AI company to come out of Korea, and one of the few in the category with real revenue rather than just pilot deployments — Q1 2026 revenue hit 24 billion won, up nearly 25%... |
Paige is the standard-bearer for clinical AI in digital pathology — the only product holding FDA De Novo authorization for primary cancer diagnosis in pathology, now backed by Tempus AI's oncology data engine. Its clinic... |
| Full review → | Full review → |
← Back to AI Directory
Comparisons cover up to 4 tools. Scores are RECATOOLS editorial assessments; verify current pricing on each vendor's site.